This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Krishnamurthy, P. Articles by Schuetz, J. D. Search for Related Content PubMed PubMed Citation Articles by Krishnamurthy, P. Articles by Schuetz, J. D.

Transporter-Mediated Protection against Thiopurine-Induced Hematopoietic Toxicity

¹ Department of Pharmaceutical Sciences and ² Animal Resource Center, St. Jude Children's Research Hospital, Memphis, Tenessee; ³ Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany, and University of Tuebingen, Tuebingen, Germany; ⁴ Department of Immunology, Institute of Basic Medical Sciences, University of Tsukuba, baraki, Japan; ⁵ Division of Clinical Pharmacology, Vanderbilt University, Nashville, Tenessee; and ⁶ Division of Clinical Pharmacology, Department of Medicine, University of Western Ontario, London, Ontario, Canada

Requests for reprints: John D. Schuetz, Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, 332 N. Lauderdale Avenue, Memphis, TN 38105. Phone: 901-495-2174; Fax: 901-525-6869; E-mail: john.schuetz{at}stjude.org.

Key Words: abc transporter • Mrp4 • thiopurine

Thiopurines are effective immunosuppressants and anticancer agents, but intracellular accumulation of their active metabolites (6-thioguanine nucleotides, 6-TGN) causes dose-limiting hematopoietic toxicity. Thiopurine S-methyltransferase deficiency is known to exacerbate thiopurine toxicity. However, many patients are highly sensitive to thiopurines for unknown reasons. We show that multidrug-resistance protein 4 (Mrp4) is abundant in myeloid progenitors and tested the role of the Mrp4, an ATP transporter of monophosphorylated nucleosides, in this unexplained thiopurine sensitivity. Mrp4-deficient mice experienced Mrp4 gene dosage-dependent toxicity caused by accumulation of 6-TGNs in their myelopoietic cells. Therefore, Mrp4 protects against thiopurine-induced hematopoietic toxicity by actively exporting thiopurine nucleotides. We then identified a single-nucleotide polymorphism (SNP) in human MRP4 (rs3765534) that dramatically reduces MRP4 function by impairing its cell membrane localization. This SNP is common (>18%) in the Japanese population and indicates that the increased sensitivity of some Japanese patients to thiopurines may reflect the greater frequency of this MRP4 SNP. [Cancer Res 2008;68(13):4983–9]

This article has been cited by other articles:

				M. Ansari, G. Sauty, M. Labuda, V. Gagne, C. Laverdiere, A. Moghrabi, D. Sinnett, and M. Krajinovic Polymorphisms in multidrug resistance-associated protein gene 4 is associated with outcome in childhood acute lymphoblastic leukemia Blood, August 13, 2009; 114(7): 1383 - 1386. [Abstract] [Full Text] [PDF]

				A. Ose, M. Ito, H. Kusuhara, K. Yamatsugu, M. Kanai, M. Shibasaki, M. Hosokawa, J. D. Schuetz, and Y. Sugiyama Limited Brain Distribution of [3R,4R,5S]-4-Acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate Phosphate (Ro 64-0802), a Pharmacologically Active Form of Oseltamivir, by Active Efflux across the Blood-Brain Barrier Mediated by Organic Anion Transporter 3 (Oat3/Slc22a8) and Multidrug Resistance-Associated Protein 4 (Mrp4/Abcc4) Drug Metab. Dispos., February 1, 2009; 37(2): 315 - 321. [Abstract] [Full Text] [PDF]